The Latest Breaking News from BioNTech

German vaccine maker BioNTech unveiled plans Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent

BioNTech SE (NASDAQ: BNTX) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have 

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…